ArticleEuropean journal of human genetics : EJHG2026
Characterisation of a Portuguese origin founder missense variant in MSH6.
Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In certain populations, founder pathogenic variants are a common cause of Lynch syndrome. Here, we report the identification of a novel Portuguese founder variant, NM_000179.3 (MSH6):c.2061 T > G (p.Cys687Trp). Our study examined 14 probands and 19 additional family members who carry this variant. With one exception, haplotype data are consistent with a single origin for all heterozygotes, likely in the Leiria District of Portugal. We investigated the clinicopathological consequences of this variant and found that, as previously reported for MSH6 pathogenic variants, (a) the presence of a pathogenic variant is not reliably associated with loss of MSH6 expression or microsatellite instability and (b) endometrial cancer is the most common associated phenotype. Due to the requirement to apply the BP5 code according to ACMG criteria, the variant is classified as a variant of uncertain significance rather than likely pathogenic. Nevertheless, the balance of evidence we present here suggests that this variant is associated with an increased risk for MSH6-related Lynch syndrome tumors.
Identifiers
42855583What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.